Terms: = Sarcomas AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2
1134 results:
1. Drugging the undruggable: Advances in targeting kras signaling in solid tumors.
Tripathi P; Kumari R; Pathak R
Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
[TBL] [Abstract] [Full Text] [Related]
2. Temporal trends and regional variability in BRAF and kras genetic testing in Denmark (2010-2022): Implications for precision medicine.
Frost MG; Jensen KJ; Jimenez-Solem E; Qvortrup C; Kuhlmann TP; Andersen JL; Høgdall E; Petersen TS
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23236. PubMed ID: 38656617
[TBL] [Abstract] [Full Text] [Related]
3. Decoding the Versatile Landscape of Autophagic Protein VMP1 in Cancer: A Comprehensive Review across Tissue Types and Regulatory Mechanisms.
Renna FJ; Gonzalez CD; Vaccaro MI
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612567
[TBL] [Abstract] [Full Text] [Related]
4. SG-Transunet: A segmentation-guided Transformer U-Net model for kras gene mutation status identification in colorectal cancer.
Ma Y; Guo Y; Cui W; Liu J; Li Y; Wang Y; Qiang Y
Comput Biol Med; 2024 May; 173():108293. PubMed ID: 38574528
[TBL] [Abstract] [Full Text] [Related]
5. Discovery of Novel Noncovalent kras G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations.
Du Z; Tu G; Gong Y; Fu X; Wu Q; Long G
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542866
[TBL] [Abstract] [Full Text] [Related]
6. Targeting
Ros J; Vaghi C; Baraibar I; Saoudi González N; Rodríguez-Castells M; García A; Alcaraz A; Salva F; Tabernero J; Elez E
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542278
[TBL] [Abstract] [Full Text] [Related]
7. Impact of kras mutation on the tumor microenvironment in colorectal cancer.
Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
[TBL] [Abstract] [Full Text] [Related]
8. Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less
Petterson J; Mustafa D; Bandaru S; Eklund EÄ; Hallqvist A; Sayin VI; Gagné A; Fagman H; Akyürek LM
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474205
[TBL] [Abstract] [Full Text] [Related]
9. Management of
Malhotra J; Nguyen D; Tan T; Semeniuk Iii GB
Clin Adv Hematol Oncol; 2024 Mar; 22(2):67-75. PubMed ID: 38446474
[TBL] [Abstract] [Full Text] [Related]
10. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma.
Yousef A; Yousef M; Zeineddine MA; More A; Fanaeian M; Chowdhury S; Knafl M; Edelkamp P; Ito I; Gu Y; Pattalachinti V; Naini ZA; Zeineddine FA; Peterson J; Alfaro K; Foo WC; Jin J; Bhutiani N; Higbie V; Scally CP; Kee B; Kopetz S; Goldstein D; Strach M; Williamson A; Aziz O; Barriuso J; Uppal A; White MG; Helmink B; Fournier KF; Raghav KP; Taggart MW; Overman MJ; Shen JP
JAMA Netw Open; 2024 Feb; 7(2):e240260. PubMed ID: 38416491
[TBL] [Abstract] [Full Text] [Related]
11. PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer.
Guo J; Yuan H; Zhu Y; Che Z; Zhang B; Zhang D; Zhou Y; Xiong L
Medicine (Baltimore); 2024 Feb; 103(8):e36770. PubMed ID: 38394518
[TBL] [Abstract] [Full Text] [Related]
12. Cascade Co
Wang L; Wang T; Zhuo Y; Xu S; Liu H; Jiang X; Lu Z; Wang X; Rao H; Wu D; Wang Y; Feng B; Sun M
J Colloid Interface Sci; 2024 May; 662():962-975. PubMed ID: 38382379
[TBL] [Abstract] [Full Text] [Related]
13. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in
Jansen RA; Mainardi S; Dias MH; Bosma A; van Dijk E; Selig R; Albrecht W; Laufer SA; Zender L; Bernards R
Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2319492121. PubMed ID: 38377196
[TBL] [Abstract] [Full Text] [Related]
14. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.
Rosell R; Pedraz-Valdunciel C; Jain A; Shivamallu C; Aguilar A
Expert Opin Investig Drugs; 2024 Mar; 33(3):171-182. PubMed ID: 38372666
[TBL] [Abstract] [Full Text] [Related]
15. Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer.
Huang Y; Jia W; Zhao G; Zhao Y; Zhang S; Li Z; Wu G
Chin Clin Oncol; 2024 Feb; 13(1):3. PubMed ID: 38372057
[TBL] [Abstract] [Full Text] [Related]
16. The association between kras and histopathological growth patterns and the impact on resection margins around vasculature and bile ducts in colorectal liver metastases.
Wong P; Wong GYM; Toon CW; Chapuis P; Hugh TJ
ANZ J Surg; 2024 Apr; 94(4):560-565. PubMed ID: 38366706
[TBL] [Abstract] [Full Text] [Related]
17. Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs.
Gu Z; Huang P; Zhao J; Luo C; Liao L; Liu A; Huang L
Int J Cancer; 2024 Jun; 154(11):1979-1986. PubMed ID: 38353428
[TBL] [Abstract] [Full Text] [Related]
18. Application of plasma circulating kras mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
[TBL] [Abstract] [Full Text] [Related]
19. Using tumor habitat-derived radiomic analysis during pretreatment
Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
[TBL] [Abstract] [Full Text] [Related]
20. AXL signal mediates adaptive resistance to kras G12C inhibitors in kras G12C-mutant tumor cells.
Morimoto K; Yamada T; Hirai S; Katayama Y; Fukui S; Sawada R; Tachibana Y; Matsui Y; Nakamura R; Ishida M; Kawachi H; Kunimasa K; Sasaki T; Nishida M; Furuya N; Watanabe S; Shiotsu S; Nishioka N; Horinaka M; Sakai T; Uehara H; Yano S; Son BK; Tokuda S; Takayama K
Cancer Lett; 2024 Apr; 587():216692. PubMed ID: 38342232
[TBL] [Abstract] [Full Text] [Related]
[Next]
